⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MBRX News
Moleculin Biotech, Inc.
Independent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline Limits
globenewswire.com
MBRX
Form 8-K
sec.gov
MBRX
Moleculin Biotech Secures Strategic Additional Patent, Strengthening Global Positioning of Annamycin
globenewswire.com
MBRX
Form 8-K
sec.gov
MBRX
Moleculin’s Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models - Data Presented at AACR 2026
globenewswire.com
MBRX
Moleculin Announces Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting
globenewswire.com
MBRX
Form 8-K
sec.gov
MBRX
Moleculin Releases Next CEO Corner Segment Highlighting Annamycin’s Non-Cardiotoxic Profile
globenewswire.com
MBRX
Gerald Haines Joins NOBLE as CFO
prnewswire.com
NMRK
MRCY
MBRX
Scalable Biotech Manufacturing Unlocks a $14B Market
prnewswire.com
MBRX
GUTS
IBRX
FATE